I would emphasise that this information and study ONLY applies to those who have had 2 specific types of Cranial bleeds and have AF and looks at the risks for these people versus net benefit resulting in a caution to doctors.
medscape.com/viewarticle/99...
At the same time, investigators of a fifth still-ongoing study of oral anticoagulation in ICH patients with AF – the ENRICH-AF study – announced that the trial's data safety monitoring board has recommended that patients with two particular types of ICH (lobar intracranial hemorrhage and convexity subarachnoid hemorrhage) stop receiving the anticoagulant being tested (edoxaban) and that no further patients with these types of ICH be enrolled into the study because of an "unacceptably high risk of recurrent hemorrhagic stroke" in those assigned to the edoxaban group.
The ENRICH-AF investigators reported this in a letter to The Lancet published online on October 12.
I know we have a few posters who have had intercranial bleeds so this information may be helpful to them, it’s not to scare those who take anticoagulants or start a discussion. Interesting though that Endoxaban is specifically mentioned.
Although the word starts with ‘anti’ - I am most definitely Pro!